At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 33 enrolled

Drug / intervention

Manganese-enhanced MRI contrast reagent +1 moredrug

Likely dose

Manganese-enhanced MRI contrast reagent 0.28 mLfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02933034

NCT02933034Phase 2Completed

Compare CT.gov

Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

Stanford University·interventional·Posted Oct 14, 2016·Updated Feb 17, 2020

In Brief

A Phase 2 clinical trial evaluating Manganese-enhanced MRI contrast reagent and Gadolinium-enhanced MRI contrast reagent for ISCHEMIC CARDIOMYOPATHY. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerance of a new intravenous diagnostic agent, SeeMore or EVP 1001-1, in patients with Cardiovascular Disease (MEMRI scan). The initial phase of this study, NCT01989195 enrolling a total of 6 patients, has been closed. This second phase adds 10 patients in a safety cohort and 60 additional patients for a total of 70 patients.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsISCHEMIC CARDIOMYOPATHY

CountriesUnited States

CollaboratorsGeneral Electric

Timeline

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartApr 2015

First PostedOct 2016

Primary CompletionFeb 2019

TodayJul 2026

First PostedOct 14, 2016

Enrollment StartApr 1, 2015

Primary CompletionFeb 3, 2019

TodayJul 2, 2026

Enrollment to primary: 3.8 yearsPosted 9.7 years ago

Interventions

Manganese-enhanced MRI contrast reagentdrug

MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).

Gadolinium-enhanced MRI contrast reagentdrug

MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).